Moreover, PML is the main therapeutic target of arsenic trioxide (ATO), a drug approved for the treatment of acute promyelocytic leukemia and shown to have anti‐HIV‐1 latency potential in vitro (Lusic et al, 2013) and in vivo (Yang et al, 2019). Here, PML is linked to acute promyelocytic leukemia.